X
ACHEMA MIDDLE EAST 2026
Pharma Advancement
DDF Summit 2025
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    idiopathic pulmonary fibrosis

    US FDA Approves Jascayd for Idiopathic Pulmonary Fibrosis

    Tissue Repair Drug

    FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

    FastTrack Review

    US FDA Launches Fast-Track Review Scheme for Generic Drugs

    AI Based Drug Discovery

    Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

    wearable drug delivery devices

    Wearable Drug Delivery Devices for On-Demand Care

    biologic drug formulation stability

    Breakthroughs in Biologic Drug Formulation Stability

    high volume injectable formulations

    Overcoming Challenges in High-Volume Injectable Formulations

    lipid nanoparticles in RNA therapies

    Lipid Nanoparticles in RNA and Gene Therapies

    Breast Cancer Therapy

    US FDA Approves Breast Cancer Therapy Inluriyo by Eli Lilly

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development Research & Development

ABBOTT JOINS FORCES WITH U.S. DEPARTMENT OF DEFENSE TO DEVELOP PORTABLE BLOOD TESTS FOR EVALUATING CONCUSSIONS

Yuvraj_pawp by Yuvraj_pawp
18th August 2014
in Research & Development

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Abbott and the United States Department of Defense today announced a collaboration with the intent to develop portable blood tests to help evaluate potential concussions, also called mild traumatic brain injuries (TBIs). As part of a multi-phased approach, the tests would be developed for Abbott’s i-STAT® System, a handheld, diagnostic analyzer that is currently used for other point-of-care testing, including among military service members. Concussions are a significant health concern for military service members. [1] With the development of new tests, physicians could use the information to positively impact the care of people with a suspected concussion.

 

“The quick and accurate diagnosis of a concussion is critical so that soldiers who are affected–whether on the battlefield or not–can be removed from duty to recover and to prevent further injury,” said Colonel Dallas C. Hack, M.D., Brain Health Coordinator, United States Army Medical Research and Materiel Command. “The Department of Defense collaboration with Abbott represents a major initiative to help improve efforts to understand this complex injury and care for wounded warriors suffering from this condition.”

 

Research suggests that certain proteins are released in the bloodstream following a brain injury, such as a concussion. Data have shown that detecting a mild traumatic brain injury can be difficult since imaging technology may not show abnormalities and symptoms can be similar to or mistaken for other medical conditions. [2], [3]

 

“Medical advances are needed to help more quickly assess concussions. The collaboration between Abbott and the Department of Defense is an important step in ensuring that military service members, and ultimately civilians, receive proper evaluation,” said Beth McQuiston, M.D., a board certified neurologist and medical director, Diagnostics, Abbott. “These new tests could open the door to many possibilities for evaluating concussions and helping clinicians optimize care and outcomes.”

 

About Traumatic Brain Injuries (TBI)

A TBI is caused by a bump, blow or jolt to the head that disrupts the normal function of the brain.[4] A TBI is classified based on the seriousness of injury, from mild to severe. [4] The majority of cases, both civilian and military, are mild TBI (also called a concussion). [1], [4]

 

TBIs are common among United States military service members. According to the Department of Defense, since 2000, more than 300,000 service members worldwide have been diagnosed with TBIs.1 The majority of TBIs in the military – eighty four percent – are caused by training, accidents, illness and non-combat assignments. [5]

 

About Abbott Point of Care

Abbott Point of Care (www.abbottpointofcare.com) is headquartered in Princeton, N.J., and develops, manufactures and markets critical medical diagnostic and data management products for rapid blood analysis. The company’s premier product is the i-STAT, a market-leading handheld blood analyzer capable of performing a panel of commonly ordered blood tests on two or three drops of blood at the patient’s side.

Previous Post

Coherus Announces CHS-1420 (Investigational Adalimumab Biosimilar) Meets Primary Endpoint In Pivotal Pharmacokinetic Clinical Study

Next Post

AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)

Related Posts

Tissue Repair Drug
Clinical Trials

FDA Clears Tissue Repair Drug AD-NP1 For Clinical Trials

7th October 2025
AI Based Drug Discovery
Drug Development

Bristol Myers, Takeda, Astex to Back AI Based Drug Discovery

1st October 2025
wearable drug delivery devices
Insights

Wearable Drug Delivery Devices for On-Demand Care

27th September 2025
biologic drug formulation stability
Drug Development

Breakthroughs in Biologic Drug Formulation Stability

27th September 2025
high volume injectable formulations
Insights

Overcoming Challenges in High-Volume Injectable Formulations

27th September 2025
Insights

Green Chemistry in Sustainable API Manufacturing

26th September 2025
Next Post

AstraZeneca announces positive top-line results from the Phase III programme of CAZ-AVI in patients with complicated intra-abdominal infections (cIAI)

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In